. . . . . . . . . "Tomoxetina"@en . . . . . . . . . . . " "@en . . "Take without regard to meals."@en . . . "The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors."@en . . . "The most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms."@en . . . "# Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16649828 # Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16555170 # Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16259536 # Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16113620 # McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17388708 # Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] Encephale. 2005 May-Jun;31(3):337-48. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16142049# Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14717619 # Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19785510 # Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Encephale. 2007 Sep;33(4 Pt 1):621-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18033153"@en . "* 0.35 L/hr/kg [after oral administration in adult extensive metabolizers] * 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]"@en . . . "Tomoxetinum"@en . "At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin."@en . . "Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]"@en . . . . . "approved"@en . . "* 0.85 L/kg"@en . . . . . "Atomoxetine"@en . . . "5 hours"@en . . "For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures."@en . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . "Tomoxetine"@en . . . . "82248-59-7"@en . "Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, \"Processes for the preparation of atomoxetine hydrochloride.\" U.S. Patent US20060211772, issued September 21, 2006."@en . . "Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food."@en . "In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected."@en . . . . . . . . . . "(-)-Tomoxetine"@en . . .